Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Armata Pharmaceuticals Inc (ARMP)
NYSE MKT:ARMP
RESEARCH TOOLSreports
Armata Pharmaceuticals (ARMP) Stock Price & Analysis
249 Followers
ARMP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.90 - $5.26
Previous Close$2.91
Volume7.00K
Average Volume (3M)12.24K
Market Cap
$105.21M
Enterprise Value$235.22M
Total Cash (Recent Filing)$37.90M
Total Debt (Recent Filing)$167.91M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Aug 14, 2024EPS Estimate
-$0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.20
Shares Outstanding36,154,617
10 Day Avg. Volume11,588
30 Day Avg. Volume12,239
Standard Deviation0.31
R-Squared0.02
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-2.32
Price to Sales (P/S)28.47
Price to Cash Flow (P/CF)-3.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue39.71
Enterprise Value/Gross Profit51.94
Enterprise Value/Ebitda-4.21
Forecast
1Y Price Target
$8.00Price Target Upside174.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Armata Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase 2 Tailwind study assessing AP-PA02 in NCFB patients with Pseudomonas aeruginosa lung infections continues to recruit patients with an uptick in enrollment noted.
Manufacturing CapacityCompletion of the build-out of its advanced biologics manufacturing cGMP facility will provide the capacity to execute its own late-stage trials while pursuing partnering opportunities.
Partnerships And FundingArmata has secured two non-dilutive partnerships and runs its own proprietary phage specific GMP manufacturing facility.
Bears Say
Convertible DebtArmata reported earnings including EPS of -$0.55, with the difference primarily driven by a charge for 'Change in fair value of convertible debt'.
EarningsArmata reported 1Q’24 earnings including EPS of -$0.69 vs. -$0.31 for consensus and analyst's -$0.34 estimate.
Financial PerformanceArmata announced 2023 results, posting 4Q23 and 2023 EPS of ($0.55) and ($1.91), respectively, compared with estimates of ($0.36) and ($1.71).
---
Ownership Overview
72.38% Insiders
0.96% Mutual Funds
0.71% Other Institutional Investors
25.94% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ARMP FAQ
What was Armata Pharmaceuticals Inc’s price range in the past 12 months?
Armata Pharmaceuticals Inc lowest stock price was $1.90 and its highest was $5.26 in the past 12 months.
What is Armata Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Armata Pharmaceuticals Inc’s upcoming earnings report date?
Armata Pharmaceuticals Inc’s upcoming earnings report date is Aug 14, 2024 which is in 17 days.
How were Armata Pharmaceuticals Inc’s earnings last quarter?
Armata Pharmaceuticals Inc released its earnings results on May 07, 2024. The company reported -$0.69 earnings per share for the quarter, missing the consensus estimate of -$0.31 by -$0.38.
Is Armata Pharmaceuticals Inc overvalued?
According to Wall Street analysts Armata Pharmaceuticals Inc’s price is currently Undervalued.
Does Armata Pharmaceuticals Inc pay dividends?
Armata Pharmaceuticals Inc does not currently pay dividends.
What is Armata Pharmaceuticals Inc’s EPS estimate?
Armata Pharmaceuticals Inc’s EPS estimate is -$0.37.
How many shares outstanding does Armata Pharmaceuticals Inc have?
Armata Pharmaceuticals Inc has 36,154,617 shares outstanding.
What happened to Armata Pharmaceuticals Inc’s price movement after its last earnings report?
Armata Pharmaceuticals Inc reported an EPS of -$0.69 in its last earnings report, missing expectations of -$0.31. Following the earnings report the stock price went down -3.497%.
Which hedge fund is a major shareholder of Armata Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in ARMP
---
Armata Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.20%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
10.64%
Trailing 12-Months
Company Description
Armata Pharmaceuticals Inc
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains. The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA.
---
ARMP Stock 12 Month Forecast
Average Price Target
$8.00
▲(174.91% Upside)
Technical Analysis
Best Analysts Covering ARMP
1 Year
1 Year Success Rate
12/27 ratings generated profit
1 Year Average Return
-0.10%
reiterated a buy rating 3 months ago
Copying Michael Higgins's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -0.10% per trade.
---